NCT06358573View on ClinicalTrials.gov

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2029

Conditions
Triple-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Interventions
DRUG

INT230-6

"INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world."

OTHER

neoadjuvant immuno-chemotherapy

Standard of care

Trial Locations (9)

4058

RECRUITING

St. Claraspital, Basel

4410

RECRUITING

Kantonsspital Baselland, Liestal

5000

RECRUITING

Tumor Zentrum Aarau, Aarau

6500

RECRUITING

EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona

7000

RECRUITING

Kantonsspital Graubünden, Chur

8091

RECRUITING

Universitätsspital Zürich - Klinik für Gynäkologie, Zurich

8401

RECRUITING

Kantonsspital Winterthur, Winterthur

9007

RECRUITING

HOCH Health Ostschweiz, Sankt Gallen

9016

RECRUITING

TBZO - Tumor- & Brustzentrum Ostschweiz, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER